Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: A randomized, placebo‐controlled study
Background: The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure. Hypothesis: The purpose of the present double‐blind, placebo‐controlle...
Gespeichert in:
| Veröffentlicht in: | Clinical cardiology (Mahwah, N.J.) N.J.), 2004-05, Vol.27 (5), p.295-299 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 299 |
|---|---|
| container_issue | 5 |
| container_start_page | 295 |
| container_title | Clinical cardiology (Mahwah, N.J.) |
| container_volume | 27 |
| creator | Berman, Marius Erman, Arie Ben‐Gal, Tuvia Dvir, Dan Georghiou, Georgios P. Stamler, Alon Vered, Yaffa Vidne, Bernardo A. Aravot, Dan |
| description | Background: The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure.
Hypothesis: The purpose of the present double‐blind, placebo‐controlled, randomized study was to assess the effect of CoQ10 on patients with end‐stage heart failure and to determine if CoQ10 can improve the pharmacological bridge to heart transplantation.
Methods: A prospective double‐blind design was used. Thirty‐two patients with end‐stage heart failure awaiting heart transplantation were randomly allocated to receive either 60 mg U/day of Ultrasome™‐‐‐CoQ10 (special preparation to increase intestinal absorption) or placebo for 3 months. All patients continued their regular medication regimen. Assessments included anamnesis with an extended questionnaire based partially on the Minnesota Living with Heart Failure Questionnaire, 6‐min walk test, blood tests for atrial natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography.
Results: Twenty‐seven patients completed the study. The study group showed significant improvement in the 6‐min walk test and a decrease in dyspnea, New York Heart Association (NYHA) classification, nocturia, and fatigue. No significant changes were noted after 3 months of treatment in echocardiography parameters (dimensions and contractility of cardiac chambers) or ANF and TNF blood levels.
Conclusion: The administration of CoQ10 to heart transplant candidates led to a significant improvement in functional status, clinical symptoms, and quality of life. However, there were no objective changes in echo measurements or ANF and TNF blood levels. Coenzyme Q10 may serve as an optional addition to the pharmacologic armamentarium of patients with end‐stage heart failure. The apparent discrepancy between significant clinical improvement and unchanged cardiac status requires further investigation. |
| doi_str_mv | 10.1002/clc.4960270512 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6654743</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72012888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4662-1ee88e08d9042c4550a5a728083d006b4bc605913753083c5d78e7bac86381ea3</originalsourceid><addsrcrecordid>eNqFkcuKFDEUhoMoTju6dSnZ6Mpqc6mqpFwMDIU3aBBB1yGVnO6OpCptkrLpWYlP4DP6JGboxmlXrgInX75zTn6EnlKypISwV8abZd21hAnSUHYPLWjHWSUFF_fRgtCWVB2T3QV6lNLXwhPJ-EN0QRsqZVeLBfrZB5huDiPgT5RgN-Gdzg6mnPDe5S2Gyf7-8StlvQG8BR0zXmvn5whY77XLbtpgo6N12uAc9ZR2Xk-5GML0Gl_jUrFhdDdgX-JyY2AIxWbClGPwHixOebaHx-jBWvsET07nJfry9s3n_n21-vjuQ3-9qkzdtqyiAFICkbYjNTN10xDdaMEkkdwS0g71YFrSdJSLhpeaaayQIAZtZMslBc0v0dXRu5uHEawpW0bt1S66UceDCtqpf28mt1Wb8F21bVOLmhfBi5Mghm8zpKxGlwz4sjOEOSnBCGVSygIuj6CJIaUI679NKFG3sakSm7qLrTx4dj7aHX7KqQDPT4BORvt1-Vnj0hknuGTdrag7cnvn4fCftqpf9WdD_AHNXrVA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72012888</pqid></control><display><type>article</type><title>Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: A randomized, placebo‐controlled study</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Berman, Marius ; Erman, Arie ; Ben‐Gal, Tuvia ; Dvir, Dan ; Georghiou, Georgios P. ; Stamler, Alon ; Vered, Yaffa ; Vidne, Bernardo A. ; Aravot, Dan</creator><creatorcontrib>Berman, Marius ; Erman, Arie ; Ben‐Gal, Tuvia ; Dvir, Dan ; Georghiou, Georgios P. ; Stamler, Alon ; Vered, Yaffa ; Vidne, Bernardo A. ; Aravot, Dan</creatorcontrib><description>Background: The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure.
Hypothesis: The purpose of the present double‐blind, placebo‐controlled, randomized study was to assess the effect of CoQ10 on patients with end‐stage heart failure and to determine if CoQ10 can improve the pharmacological bridge to heart transplantation.
Methods: A prospective double‐blind design was used. Thirty‐two patients with end‐stage heart failure awaiting heart transplantation were randomly allocated to receive either 60 mg U/day of Ultrasome™‐‐‐CoQ10 (special preparation to increase intestinal absorption) or placebo for 3 months. All patients continued their regular medication regimen. Assessments included anamnesis with an extended questionnaire based partially on the Minnesota Living with Heart Failure Questionnaire, 6‐min walk test, blood tests for atrial natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography.
Results: Twenty‐seven patients completed the study. The study group showed significant improvement in the 6‐min walk test and a decrease in dyspnea, New York Heart Association (NYHA) classification, nocturia, and fatigue. No significant changes were noted after 3 months of treatment in echocardiography parameters (dimensions and contractility of cardiac chambers) or ANF and TNF blood levels.
Conclusion: The administration of CoQ10 to heart transplant candidates led to a significant improvement in functional status, clinical symptoms, and quality of life. However, there were no objective changes in echo measurements or ANF and TNF blood levels. Coenzyme Q10 may serve as an optional addition to the pharmacologic armamentarium of patients with end‐stage heart failure. The apparent discrepancy between significant clinical improvement and unchanged cardiac status requires further investigation.</description><identifier>ISSN: 0160-9289</identifier><identifier>EISSN: 1932-8737</identifier><identifier>DOI: 10.1002/clc.4960270512</identifier><identifier>PMID: 15188947</identifier><identifier>CODEN: CLCADC</identifier><language>eng</language><publisher>New York: Wiley Periodicals, Inc</publisher><subject>Adult ; Aged ; Atrial Natriuretic Factor - blood ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiotonic Agents - therapeutic use ; Clinical Investigation ; Clinical Investigations ; coenzyme Q10 ; Coenzymes ; Double-Blind Method ; Exercise Tolerance ; Female ; Heart ; heart failure ; Heart Failure - blood ; Heart Failure - diagnostic imaging ; Heart Failure - drug therapy ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Heart Transplantation ; Humans ; Male ; Medical sciences ; Middle Aged ; Prospective Studies ; Quality of Life ; Recovery of Function ; Severity of Illness Index ; Tumor Necrosis Factor-alpha - metabolism ; Ubiquinone - analogs & derivatives ; Ubiquinone - therapeutic use ; Ultrasonography ; Waiting Lists</subject><ispartof>Clinical cardiology (Mahwah, N.J.), 2004-05, Vol.27 (5), p.295-299</ispartof><rights>Copyright © 2004 Wiley Periodicals, Inc.</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4662-1ee88e08d9042c4550a5a728083d006b4bc605913753083c5d78e7bac86381ea3</citedby><cites>FETCH-LOGICAL-c4662-1ee88e08d9042c4550a5a728083d006b4bc605913753083c5d78e7bac86381ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6654743/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6654743/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,27901,27902,45550,45551,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15738292$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15188947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berman, Marius</creatorcontrib><creatorcontrib>Erman, Arie</creatorcontrib><creatorcontrib>Ben‐Gal, Tuvia</creatorcontrib><creatorcontrib>Dvir, Dan</creatorcontrib><creatorcontrib>Georghiou, Georgios P.</creatorcontrib><creatorcontrib>Stamler, Alon</creatorcontrib><creatorcontrib>Vered, Yaffa</creatorcontrib><creatorcontrib>Vidne, Bernardo A.</creatorcontrib><creatorcontrib>Aravot, Dan</creatorcontrib><title>Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: A randomized, placebo‐controlled study</title><title>Clinical cardiology (Mahwah, N.J.)</title><addtitle>Clin Cardiol</addtitle><description>Background: The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure.
Hypothesis: The purpose of the present double‐blind, placebo‐controlled, randomized study was to assess the effect of CoQ10 on patients with end‐stage heart failure and to determine if CoQ10 can improve the pharmacological bridge to heart transplantation.
Methods: A prospective double‐blind design was used. Thirty‐two patients with end‐stage heart failure awaiting heart transplantation were randomly allocated to receive either 60 mg U/day of Ultrasome™‐‐‐CoQ10 (special preparation to increase intestinal absorption) or placebo for 3 months. All patients continued their regular medication regimen. Assessments included anamnesis with an extended questionnaire based partially on the Minnesota Living with Heart Failure Questionnaire, 6‐min walk test, blood tests for atrial natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography.
Results: Twenty‐seven patients completed the study. The study group showed significant improvement in the 6‐min walk test and a decrease in dyspnea, New York Heart Association (NYHA) classification, nocturia, and fatigue. No significant changes were noted after 3 months of treatment in echocardiography parameters (dimensions and contractility of cardiac chambers) or ANF and TNF blood levels.
Conclusion: The administration of CoQ10 to heart transplant candidates led to a significant improvement in functional status, clinical symptoms, and quality of life. However, there were no objective changes in echo measurements or ANF and TNF blood levels. Coenzyme Q10 may serve as an optional addition to the pharmacologic armamentarium of patients with end‐stage heart failure. The apparent discrepancy between significant clinical improvement and unchanged cardiac status requires further investigation.</description><subject>Adult</subject><subject>Aged</subject><subject>Atrial Natriuretic Factor - blood</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiotonic Agents - therapeutic use</subject><subject>Clinical Investigation</subject><subject>Clinical Investigations</subject><subject>coenzyme Q10</subject><subject>Coenzymes</subject><subject>Double-Blind Method</subject><subject>Exercise Tolerance</subject><subject>Female</subject><subject>Heart</subject><subject>heart failure</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - diagnostic imaging</subject><subject>Heart Failure - drug therapy</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Heart Transplantation</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Recovery of Function</subject><subject>Severity of Illness Index</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Ubiquinone - analogs & derivatives</subject><subject>Ubiquinone - therapeutic use</subject><subject>Ultrasonography</subject><subject>Waiting Lists</subject><issn>0160-9289</issn><issn>1932-8737</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuKFDEUhoMoTju6dSnZ6Mpqc6mqpFwMDIU3aBBB1yGVnO6OpCptkrLpWYlP4DP6JGboxmlXrgInX75zTn6EnlKypISwV8abZd21hAnSUHYPLWjHWSUFF_fRgtCWVB2T3QV6lNLXwhPJ-EN0QRsqZVeLBfrZB5huDiPgT5RgN-Gdzg6mnPDe5S2Gyf7-8StlvQG8BR0zXmvn5whY77XLbtpgo6N12uAc9ZR2Xk-5GML0Gl_jUrFhdDdgX-JyY2AIxWbClGPwHixOebaHx-jBWvsET07nJfry9s3n_n21-vjuQ3-9qkzdtqyiAFICkbYjNTN10xDdaMEkkdwS0g71YFrSdJSLhpeaaayQIAZtZMslBc0v0dXRu5uHEawpW0bt1S66UceDCtqpf28mt1Wb8F21bVOLmhfBi5Mghm8zpKxGlwz4sjOEOSnBCGVSygIuj6CJIaUI679NKFG3sakSm7qLrTx4dj7aHX7KqQDPT4BORvt1-Vnj0hknuGTdrag7cnvn4fCftqpf9WdD_AHNXrVA</recordid><startdate>200405</startdate><enddate>200405</enddate><creator>Berman, Marius</creator><creator>Erman, Arie</creator><creator>Ben‐Gal, Tuvia</creator><creator>Dvir, Dan</creator><creator>Georghiou, Georgios P.</creator><creator>Stamler, Alon</creator><creator>Vered, Yaffa</creator><creator>Vidne, Bernardo A.</creator><creator>Aravot, Dan</creator><general>Wiley Periodicals, Inc</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200405</creationdate><title>Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: A randomized, placebo‐controlled study</title><author>Berman, Marius ; Erman, Arie ; Ben‐Gal, Tuvia ; Dvir, Dan ; Georghiou, Georgios P. ; Stamler, Alon ; Vered, Yaffa ; Vidne, Bernardo A. ; Aravot, Dan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4662-1ee88e08d9042c4550a5a728083d006b4bc605913753083c5d78e7bac86381ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Atrial Natriuretic Factor - blood</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiotonic Agents - therapeutic use</topic><topic>Clinical Investigation</topic><topic>Clinical Investigations</topic><topic>coenzyme Q10</topic><topic>Coenzymes</topic><topic>Double-Blind Method</topic><topic>Exercise Tolerance</topic><topic>Female</topic><topic>Heart</topic><topic>heart failure</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - diagnostic imaging</topic><topic>Heart Failure - drug therapy</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Heart Transplantation</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Recovery of Function</topic><topic>Severity of Illness Index</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Ubiquinone - analogs & derivatives</topic><topic>Ubiquinone - therapeutic use</topic><topic>Ultrasonography</topic><topic>Waiting Lists</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berman, Marius</creatorcontrib><creatorcontrib>Erman, Arie</creatorcontrib><creatorcontrib>Ben‐Gal, Tuvia</creatorcontrib><creatorcontrib>Dvir, Dan</creatorcontrib><creatorcontrib>Georghiou, Georgios P.</creatorcontrib><creatorcontrib>Stamler, Alon</creatorcontrib><creatorcontrib>Vered, Yaffa</creatorcontrib><creatorcontrib>Vidne, Bernardo A.</creatorcontrib><creatorcontrib>Aravot, Dan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cardiology (Mahwah, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berman, Marius</au><au>Erman, Arie</au><au>Ben‐Gal, Tuvia</au><au>Dvir, Dan</au><au>Georghiou, Georgios P.</au><au>Stamler, Alon</au><au>Vered, Yaffa</au><au>Vidne, Bernardo A.</au><au>Aravot, Dan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: A randomized, placebo‐controlled study</atitle><jtitle>Clinical cardiology (Mahwah, N.J.)</jtitle><addtitle>Clin Cardiol</addtitle><date>2004-05</date><risdate>2004</risdate><volume>27</volume><issue>5</issue><spage>295</spage><epage>299</epage><pages>295-299</pages><issn>0160-9289</issn><eissn>1932-8737</eissn><coden>CLCADC</coden><abstract>Background: The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure.
Hypothesis: The purpose of the present double‐blind, placebo‐controlled, randomized study was to assess the effect of CoQ10 on patients with end‐stage heart failure and to determine if CoQ10 can improve the pharmacological bridge to heart transplantation.
Methods: A prospective double‐blind design was used. Thirty‐two patients with end‐stage heart failure awaiting heart transplantation were randomly allocated to receive either 60 mg U/day of Ultrasome™‐‐‐CoQ10 (special preparation to increase intestinal absorption) or placebo for 3 months. All patients continued their regular medication regimen. Assessments included anamnesis with an extended questionnaire based partially on the Minnesota Living with Heart Failure Questionnaire, 6‐min walk test, blood tests for atrial natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography.
Results: Twenty‐seven patients completed the study. The study group showed significant improvement in the 6‐min walk test and a decrease in dyspnea, New York Heart Association (NYHA) classification, nocturia, and fatigue. No significant changes were noted after 3 months of treatment in echocardiography parameters (dimensions and contractility of cardiac chambers) or ANF and TNF blood levels.
Conclusion: The administration of CoQ10 to heart transplant candidates led to a significant improvement in functional status, clinical symptoms, and quality of life. However, there were no objective changes in echo measurements or ANF and TNF blood levels. Coenzyme Q10 may serve as an optional addition to the pharmacologic armamentarium of patients with end‐stage heart failure. The apparent discrepancy between significant clinical improvement and unchanged cardiac status requires further investigation.</abstract><cop>New York</cop><pub>Wiley Periodicals, Inc</pub><pmid>15188947</pmid><doi>10.1002/clc.4960270512</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0160-9289 |
| ispartof | Clinical cardiology (Mahwah, N.J.), 2004-05, Vol.27 (5), p.295-299 |
| issn | 0160-9289 1932-8737 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6654743 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals; PubMed Central |
| subjects | Adult Aged Atrial Natriuretic Factor - blood Biological and medical sciences Cardiology. Vascular system Cardiotonic Agents - therapeutic use Clinical Investigation Clinical Investigations coenzyme Q10 Coenzymes Double-Blind Method Exercise Tolerance Female Heart heart failure Heart Failure - blood Heart Failure - diagnostic imaging Heart Failure - drug therapy Heart failure, cardiogenic pulmonary edema, cardiac enlargement Heart Transplantation Humans Male Medical sciences Middle Aged Prospective Studies Quality of Life Recovery of Function Severity of Illness Index Tumor Necrosis Factor-alpha - metabolism Ubiquinone - analogs & derivatives Ubiquinone - therapeutic use Ultrasonography Waiting Lists |
| title | Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: A randomized, placebo‐controlled study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T12%3A34%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Coenzyme%20Q10%20in%20patients%20with%20end%E2%80%90stage%20heart%20failure%20awaiting%20cardiac%20transplantation:%20A%20randomized,%20placebo%E2%80%90controlled%20study&rft.jtitle=Clinical%20cardiology%20(Mahwah,%20N.J.)&rft.au=Berman,%20Marius&rft.date=2004-05&rft.volume=27&rft.issue=5&rft.spage=295&rft.epage=299&rft.pages=295-299&rft.issn=0160-9289&rft.eissn=1932-8737&rft.coden=CLCADC&rft_id=info:doi/10.1002/clc.4960270512&rft_dat=%3Cproquest_pubme%3E72012888%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72012888&rft_id=info:pmid/15188947&rfr_iscdi=true |